GlobeNews Wire

Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study

May 08, 2026 20:45 ET  | Source: Amplia Therapuetics Limited Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Amplia…

1 month ago

DSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing

May 08, 2026 17:00 ET  | Source: DSS, Inc. ROCHESTER, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE…

1 month ago

NVIDIA Names Suzanne Nora Johnson to Board of Directors

SANTA CLARA, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- NVIDIA today announced that it has named to its board of…

1 month ago

SalesCloser Announces Collaboration with Twilio to Accelerate Customer Deployments

Collaboration with Twilio, a leading global cloud communications platform1, aims to streamline enterprise-grade phone number activation, reduce compliance friction, and…

1 month ago

Crypto News Today: AlphaPepe Presale Near Sell-Out While Bitcoin Price Prediction Points To $250k

MONACO, May 08, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe as Stage 15 moves toward a…

1 month ago

Crypto News: AlphaPepe Advances Toward Q2 Exchange Listing While XRP Price Prediction Targets $10

MONACO, May 08, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe as the project advances toward its Q2…

1 month ago

FormFactor to Ring the Nasdaq Stock Market Closing Bell on May 11th, 2026

May 08, 2026 18:11 ET  | Source: FormFactor, Inc. LIVERMORE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- FormFactor, Inc. (NASDAQ:…

1 month ago

James Cacioppo Files Updated Early Warning Report

May 08, 2026 16:05 ET  | Source: Jushi Holdings Inc. BOCA RATON, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- James…

1 month ago

Invitation to attend the annual and the extraordinary shareholders meetings of the Company to be held on June 10, 2026

REGULATED INFORMATIONMay 8, 2026, 10:05pm CET / 4:05pm ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter…

1 month ago

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular…

1 month ago